Upgrade to SI Premium - Free Trial

MannKind (MNKD)

3.84 -0.21 (5.19%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/12/26)

Latest Headlines

Form 4 MANNKIND CORP For: Jul 15 Filed by: Prentiss Christopher B July 17, 2026 9:48 PM - SEC Filing Form 4 MANNKIND CORP For: Jul 15 Filed by: Marasco Dominic July 17, 2026 9:47 PM - SEC Filing Form 4 MANNKIND CORP For: Jul 15 Filed by: Tross Stuart A July 17, 2026 9:45 PM - SEC Filing Form 4 MANNKIND CORP For: Jul 15 Filed by: Castagna Michael July 17, 2026 9:45 PM - SEC Filing Form 4 MANNKIND CORP For: Jul 15 Filed by: Singh Sanjay R July 17, 2026 9:44 PM - SEC Filing Form 4 MANNKIND CORP For: Jul 15 Filed by: Thomson David July 17, 2026 9:44 PM - SEC Filing Form 4 MANNKIND CORP For: Jul 15 Filed by: Binder Steven B. July 17, 2026 9:43 PM - SEC Filing Form 144 MANNKIND CORP Filed by: Thomson David July 17, 2026 4:22 PM - SEC Filing Form 144 MANNKIND CORP Filed by: Binder Steven B. July 17, 2026 4:21 PM - SEC Filing MannKind receives Breakthrough T1D grant for pediatric Afrezza trial June 23, 2026 9:00 AM - StreetInsider MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D June 23, 2026 9:00 AM - StreetInsider Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (A June 5, 2026 7:35 PM - StreetInsider MannKind completes randomization in phase 1b study for IPF treatment June 3, 2026 6:05 AM - StreetInsider MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF June 3, 2026 6:05 AM - StreetInsider Form 8-K MANNKIND CORP For: May 29 June 2, 2026 8:01 AM - SEC Filing MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval May 29, 2026 2:00 PM - Globe NewsWire MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval May 29, 2026 2:00 PM - StreetInsider US FDA approves MannKind's inhaled insulin for children May 29, 2026 12:44 PM - StreetInsider MannKind gets FDA approval for inhaled insulin in children ages 6 and up May 29, 2026 12:30 PM - StreetInsider MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes May 29, 2026 12:30 PM - StreetInsider Form 8-K MANNKIND CORP For: May 27 May 28, 2026 8:37 AM - SEC Filing MannKind to Present at Jefferies Global Healthcare Conference May 27, 2026 4:00 PM - StreetInsider MannKind presents Afrezza data at diabetes conference May 27, 2026 9:06 AM - StreetInsider MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems May 27, 2026 9:05 AM - StreetInsider Form 4 MANNKIND CORP For: May 20 Filed by: Friedman Michael A May 22, 2026 9:10 PM - SEC Filing Form 4 MANNKIND CORP For: May 20 Filed by: Consiglio Ronald J May 22, 2026 9:00 PM - SEC Filing Form 4 MANNKIND CORP For: May 20 Filed by: Binder Steven B. May 22, 2026 8:56 PM - SEC Filing Form 4 MANNKIND CORP For: May 20 Filed by: Grancio Jennifer May 22, 2026 8:53 PM - SEC Filing Form 4 MANNKIND CORP For: May 20 Filed by: HOOPER ANTHONY C May 22, 2026 8:51 PM - SEC Filing Form 4 MANNKIND CORP For: May 20 Filed by: Shannon James Samuel May 22, 2026 8:50 PM - SEC Filing Form 4 MANNKIND CORP For: May 20 Filed by: Tross Stuart A May 22, 2026 8:49 PM - SEC Filing Form 4 MANNKIND CORP For: May 20 Filed by: Marasco Dominic May 22, 2026 8:49 PM - SEC Filing Form 4 MANNKIND CORP For: May 20 Filed by: MUNDKUR CHRISTINE May 22, 2026 8:48 PM - SEC Filing Form 4 MANNKIND CORP For: May 20 Filed by: Kay Sabrina May 22, 2026 8:48 PM - SEC Filing Form 8-K MANNKIND CORP For: May 20 May 22, 2026 5:18 PM - SEC Filing Form 144/A MANNKIND CORP Filed by: Thomson David May 14, 2026 4:51 PM - SEC Filing Form 4 MANNKIND CORP For: May 11 Filed by: Tross Stuart A May 13, 2026 8:30 PM - SEC Filing Form 4 MANNKIND CORP For: May 11 Filed by: Castagna Michael May 13, 2026 8:30 PM - SEC Filing Form 4 MANNKIND CORP For: May 11 Filed by: Thomson David May 13, 2026 8:30 PM - SEC Filing Form 4 MANNKIND CORP For: May 11 Filed by: Binder Steven B. May 13, 2026 8:30 PM - SEC Filing Form 144 MANNKIND CORP Filed by: Thomson David May 12, 2026 4:35 PM - SEC Filing Form 144 MANNKIND CORP Filed by: Binder Steven B. May 12, 2026 4:35 PM - SEC Filing Form SCHEDULE 13G MANNKIND CORP Filed by: STATE STREET CORP May 12, 2026 11:29 AM - SEC Filing Form 4/A MANNKIND CORP For: Mar 10 Filed by: Castagna Michael May 8, 2026 9:20 PM - SEC Filing MannKind (MNKD) PT Raised to $10 at Wells Fargo May 7, 2026 8:24 AM - StreetInsider MannKind (MNKD) PT Raised to $10 at H.C. Wainwright May 7, 2026 7:44 AM - StreetInsider MannKind (MNKD) PT Lowered to $7 at Mizuho May 7, 2026 6:50 AM - StreetInsider MannKind (MNKD) Misses Q1 EPS by 1c May 6, 2026 4:09 PM - StreetInsider Form 10-Q MANNKIND CORP For: Mar 31 May 6, 2026 4:07 PM - SEC Filing Form 8-K MANNKIND CORP For: May 06 May 6, 2026 4:04 PM - SEC Filing MannKind Reports First Quarter 2026 Financial Results and Provides Business Update May 6, 2026 4:01 PM - StreetInsider MannKind develops dry powder inhaler for pulmonary hypertension treatment May 6, 2026 6:31 AM - StreetInsider MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases May 6, 2026 6:30 AM - Globe NewsWire MannKind to Report First Quarter 2026 Financial Results on May 6, 2026 April 29, 2026 4:01 PM - StreetInsider MannKind (MNKD) PT Raised to $8 at Wells Fargo April 28, 2026 7:36 AM - StreetInsider Form 4 MANNKIND CORP For: Apr 22 Filed by: Prentiss Christopher B April 24, 2026 9:30 PM - SEC Filing Full Article List